Q-omics provides the consensus-scored OTOP1 profile across patient tissues and cancer cell-line models. OTOP1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, OTOP1 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, OTOP1 RNA expression shows 9,575 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where OTOP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OTOP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OTOP1 survival associations across molecular data types. OTOP1 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OTOP1 RNA expression–survival associations across cancer types. High OTOP1 expression shows unfavorable associations in KIRC, UCS, SCLC and SARC, but favorable associations in LUSC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for OTOP1 RNA expression.
This table summarizes OTOP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for OTOP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OTOP1 shows lower tumor expression in HNSC and STAD and higher tumor expression in COAD, UCEC, LUSC and LUAD. The COAD box plot shows higher OTOP1 RNA expression in tumor versus normal tissue (log2 FC = +0.220, t-test p = .002).
This table shows molecular features associated with OTOP1 in patient tissues and cancer cell lines. In patient samples, OTOP1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, OTOP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
